2'-O-(2-ethylacetyl)adenosine | 851779-57-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2'-O-(2-ethylacetyl)adenosine
• 英文别名: 2'-o-Monobutyryladenosine；[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] butanoate
• CAS: 851779-57-2
• 化学式: C₁₄H₁₉N₅O₅
• 分子量: 337.335
• InChiKey: ZFVXOVJSEIPINR-FRJWGUMJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  溴乙酸乙酯 、 腺苷 在 NaH 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2'-O-(2-ethylacetyl)adenosine
  参考文献：
  名称：

  Oligonucleotide analogs having modified dimers

  摘要：

  提供具有核糖糖基在5'核苷和3'核苷中具有2'修饰糖的改性二聚体。这些改性二聚体在制备寡核苷酸类似物方面非常有用，相比于天然寡核苷酸，具有增强性能，包括增加核酸酶抗性、增强结合亲和力和改善蛋白结合。

  公开号：

  US06420549B1

文献信息

• [EN] INJECTABLE HYDROGELS AND USES THEREOF<br/>[FR] HYDROGELS INJECTABLES ET UTILISATIONS CORRESPONDANTES
  申请人：UNIV STRASBOURG

  公开号：WO2018134268A1

  公开（公告）日：2018-07-26

  The invention relates to a hydrogel, in particular degradable or non degradable, comprising monomers of formula (I) and organosilica particles or porous silicon particles covalently bound thereto, optionally with non covalently bound organosilica and/or silicon particles mixed therewith, in particular degradable organosilica nanoparticles or core-shell nanocapsules; pharmaceutical, veterinary or cosmetic compositions thereof; and uses thereof as a medicament. The present invention finds applications in the therapeutic and diagnostic medical technical fields and also in cosmetic and veterinary technical fields.

  该发明涉及一种水凝胶，特别是可降解或不可降解的水凝胶，包括式(I)的单体和共价结合在一起的有机硅颗粒或多孔硅颗粒，可选地与非共价结合的有机硅和/或硅颗粒混合在一起，特别是可降解的有机硅纳米颗粒或核壳纳米胶囊；以及其制备的药用、兽医或化妆品组合物；以及作为药物的用途。该发明在治疗和诊断医疗技术领域以及化妆品和兽医技术领域中找到应用。
• AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
  申请人：——

  公开号：US20030088079A1

  公开（公告）日：2003-05-08

  Nucleosidic monomers and oligomeric compounds prepared therefrom are provided which have increased nuclease resistance, substituent groups (such as 2′-aminooxy groups) for increasing binding affinity to complementary strand, and regions of 2′-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H. Such oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.

  提供具有增强核酸酶抵抗性的核苷酸单体和由此制备的寡聚化合物，这些化合物具有取代基团（例如2'-氨氧基基团）以增加与互补链的结合亲和力，并具有激活RNase H的2'-脱氧-赤霉糖核苷酸区域。这些寡聚化合物可用于诊断和其他研究目的，用于调节生物体中蛋白质的表达，并用于对易受寡核苷酸治疗的其他疾病进行诊断、检测和治疗。
• AMINOOXY-MODIFIED OLIGONUCLEOTIDES
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：EP0977767B1

  公开（公告）日：2007-09-19
• INJECTABLE HYDROGELS AND USES THEREOF
  申请人：UNIVERSITE DE STRASBOURG

  公开号：US20200138711A1

  公开（公告）日：2020-05-07

  The invention relates to a hydrogel, in particular degradable or non degradable, comprising monomers of formula (I) and organosilica particles or porous silicon particles covalently bound thereto, optionally with non covalently bound organosilica and/or silicon particles mixed therewith, in particular degradable organosilica nanoparticles or core-shell nanocapsules; pharmaceutical, veterinary or cosmetic compositions thereof; and uses thereof as a medicament. The present invention finds applications in the therapeutic and diagnostic medical technical fields and also in cosmetic and veterinary technical fields.
• US6124502A
  申请人：——

  公开号：US6124502A

  公开（公告）日：2000-09-26